Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vycor Medical (VYCO) Profit After Tax (2016 - 2025)

Vycor Medical has reported Profit After Tax over the past 16 years, most recently at -$60450.0 for Q4 2025.

  • Quarterly Profit After Tax fell 804.26% to -$60450.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$70141.0 through Dec 2025, up 34.48% year-over-year, with the annual reading at -$70190.0 for FY2025, 34.37% up from the prior year.
  • Profit After Tax was -$60450.0 for Q4 2025 at Vycor Medical, down from $4936.0 in the prior quarter.
  • Over five years, Profit After Tax peaked at $68406.0 in Q2 2023 and troughed at -$242919.0 in Q1 2021.
  • The 5-year median for Profit After Tax is -$44996.5 (2023), against an average of -$53428.1.
  • Year-over-year, Profit After Tax tumbled 1566.41% in 2022 and then soared 337.97% in 2025.
  • A 5-year view of Profit After Tax shows it stood at -$186104.0 in 2021, then soared by 40.18% to -$111336.0 in 2022, then rose by 19.2% to -$89961.0 in 2023, then surged by 92.57% to -$6685.0 in 2024, then tumbled by 804.26% to -$60450.0 in 2025.
  • Per Business Quant, the three most recent readings for VYCO's Profit After Tax are -$60450.0 (Q4 2025), $4936.0 (Q3 2025), and $23887.0 (Q2 2025).